Emergency diagnostic tests

for cardio-vascular disease

A breakthrough technology

using magnetic nanoparticles

International publications

and strong patent protection

Committed to saving lives

and decreasing public health costs

A multidisciplinary team with strong experience and expertise

with a focus on the market

Magnisense obtains the CE certification for its MiAG product │ Magnisense set up its QC, manufacturing and logistics organization │Magnisense strengthens its commercial team │Magnisense moved into its new headquarters in Paris.


Le Campus

Magnisense moved its R&D Lab to “Le Campus”, a new facility in Lyon, in the heart of the worldwide healthcare competitiveness cluster Lyon biopole. Its head office is located in the Paris based biomedical business cluster Medicen.

Le Campus

Magnisense, improve Emergency Diag to save lives


MAGNISENSE Designs, registers and commercializes tests for emergency diagnsotic of cardiovascular diseases.


MiAG, CE marked by Magnisense, is a « best in class » product for the emergency diagnostic of cardiovascular diseases, in particular for the diagnosis of acut heart failure and heart attack.

It allows to quantify cardiac biomarkers in blood, whose dosage is recommended by the healthcare authorities and is reimbursed. The MiAG tests are performed in 15 minutes directly in whole blood nearby the patient, by using a mobile instrument with reduced maintenance, The tests are easy to use, robust with a competitive price. The quantitative results are obtained with a complete traceability and a outstanding correlation with the results obtained using big automates,.

MiAG was developed by using the company breakthrough technology based on the use of magnetic nanoparticles. This technology is worldwide patented.


In an environment where the healthcare structures are centralised and the ambulatory medicine is favoured, MiAG is bringing on the market a solution for patients, healthcare profesionnals and public health organisations.


It contributes to improve emergency medicine by saving lives and decreasing patients disabilities. It allows to set up innovative patient management pathways at the hospital. It also contribute to reduce the direct and indirect public costs associated to the management of cardiovascular diseases which explode.


Learn more